Changes

C/EBP-Alpha   

C/EBP-Alpha   

==Genomic Location==

==Genomic Location==

chr19:33,790,840-33,793,430 [hg19]

chr19:33,790,840-33,793,430 [hg19]

==Cancer Category/Type==

==Cancer Category/Type==

Put your text here

Put your text here

   

   

==External Links==

==External Links==

==References==

==References==

=== EXAMPLE Book ===

=== Book ===

1. Swerdlow SH et al. (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, Volume 2, IARC Press: Lyon 2017, p. 142-144, p. 124-126

1. Swerdlow SH et al. (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition, Volume 2, IARC Press: Lyon 2017, p. 142-144, p. 124-126

=== EXAMPLE Journal Article ===

=== Journal Article ===

2. Tawana K, et al., (2015)  Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 126(10):1214-23, PMID: 26162409

2. Tawana K, et al., (2015)  Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood 126(10):1214-23, PMID: 26162409

== Notes ==

== Notes ==

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.